Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.
about
Dual Role of ROS as Signal and Stress Agents: Iron Tips the Balance in favor of Toxic EffectsAntioxidant Intake and Antitumor Therapy: Toward Nutritional Recommendations for Optimal ResultsMitochondria and mitophagy: the yin and yang of cell death controlDexrazoxane Diminishes Doxorubicin-Induced Acute Ovarian Damage and Preserves Ovarian Function and Fecundity in MiceSulforaphane protects the heart from doxorubicin-induced toxicitySex-specific cardiac cardiolipin remodelling after doxorubicin treatmentQuantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugsA Biophysical Systems Approach to Identifying the Pathways of Acute and Chronic Doxorubicin Mitochondrial CardiotoxicityProtective effect of 23-hydroxybetulinic acid on doxorubicin-induced cardiotoxicity: a correlation with the inhibition of carbonyl reductase-mediated metabolismMolecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up.Angiotensin-converting enzyme 2 overexpression protects against doxorubicin-induced cardiomyopathy by multiple mechanisms in rats.Nrf2 deficiency exaggerates doxorubicin-induced cardiotoxicity and cardiac dysfunction.Mice lacking mitochondrial ferritin are more sensitive to doxorubicin-mediated cardiotoxicity.A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity.Twisting and ironing: doxorubicin cardiotoxicity by mitochondrial DNA damage.N-3 polyunsaturated fatty acids decrease levels of doxorubicin-induced reactive oxygen species in cardiomyocytes -- involvement of uncoupling protein UCP2.Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cellsPhysiological, pharmacological and toxicological considerations of drug-induced structural cardiac injuryLC-UV/MS methods for the analysis of prochelator-boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH)Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms.A metabolomic study of rats with doxorubicin-induced cardiomyopathy and Shengmai injection treatment.Cyclovirobuxine D Attenuates Doxorubicin-Induced Cardiomyopathy by Suppression of Oxidative Damage and Mitochondrial Biogenesis Impairment.Cannabidiol Protects against Doxorubicin-Induced Cardiomyopathy by Modulating Mitochondrial Function and Biogenesis.AZT-induced mitochondrial toxicity: an epigenetic paradigm for dysregulation of gene expression through mitochondrial oxidative stressAnalysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy.Cardiotoxicity of anthracycline therapy: current perspectivesDoxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification.Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC-ONC Study--A Single-Center, Blinded, Randomized Controlled Trial.Selective cytoprotective effect of histamine on doxorubicin-induced hepatic and cardiac toxicity in animal models.Protection from oxidative and electrophilic stress in the Gsta4-null mouse heart.Overproduction of reactive oxygen species - obligatory or not for induction of apoptosis by anticancer drugsAll-trans retinoic acid protects against doxorubicin-induced cardiotoxicity by activating the ERK2 signalling pathwayCardiac toxicity of anticancer agents.Novel aspects of ROS signalling in heart failure.The role of iron in anthracycline cardiotoxicity.Cardiac complications in childhood cancer survivors treated with anthracyclines.Prophylactic supplementation of resveratrol is more effective than its therapeutic use against doxorubicin induced cardiotoxicity.Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations.Oxidative stress does not play a primary role in the toxicity induced with clinical doses of doxorubicin in myocardial H9c2 cells.Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer.
P2860
Q26752455-7DD708A8-E379-44B6-BE46-9FE56F4BD773Q26774897-B25E2173-2445-439F-B384-EA1DAAEDF82CQ27028020-3D2256E0-4A09-4F8A-8D13-47F0E4217E85Q27345163-81851BF4-F6BC-4210-8B27-79B1ABD90F37Q28387218-48D521FC-2F65-4E42-97A3-2C157E932AB2Q28391344-F5513676-C73A-4B7D-8DDF-F2B65C07CE66Q28539989-4FE6C568-F8D4-4F8C-A4E6-8ECD3D91A614Q28553631-52B89807-A54D-4508-8267-3CBB30741017Q28606782-DB35D592-7914-408E-A3D2-AC9BF77F5852Q33578496-1273A234-8496-47AC-9994-5032A07FD3ACQ33648557-95BE2B2A-759C-4AD4-8F75-F22F478CB805Q33660939-20C92CAD-9694-4ACB-9A8B-275ED08E28A7Q33985016-EFF17396-DADE-467D-B525-134041F7370CQ34219095-B6A8DE74-A01A-4AF7-A50D-E9AA9431E072Q34375948-884AA471-A2D9-4F18-8FF2-8A2C4435A564Q34544057-222B54AB-E1A6-46B6-9177-7B6C1BDB1386Q35014803-DDFB575E-9684-47ED-9B46-2538C4C766C7Q35039202-E527955A-77EA-402C-AED9-8832B408CF33Q35071893-0EFFF86A-3654-4DD9-8CC1-0D87A6444576Q35296244-85773BC9-5CC3-4EB2-A0AB-70E3722D29D7Q35566390-B869ED83-67CA-4C34-8127-6706A6AA4305Q35657024-3645B37E-A8B0-403B-80D6-821903E668EDQ35707221-AA4F9F3F-CA8C-42B1-A9CF-0EE9A7DB7A80Q36122838-497CF595-47BE-4E52-AEB5-43B253A23507Q36296724-0FB74969-E398-436A-A6BF-5A0AEBA9AA35Q36845348-455F9D19-ED0B-4757-AA2D-DC65A90B373CQ36869450-BDA1C37E-61A2-4006-8AC3-B72652BFAB50Q36894836-F63E253B-B1FC-4AF2-91BC-BAC141CFB3ADQ37164327-60330104-3DDB-4338-B14A-4D947D4549CCQ37228548-CC99971B-C3F9-4ABA-9B49-A0F9E45DAC3CQ37246924-06604B4D-366A-4BB6-88D0-2F005558A1E9Q37686126-B45DF401-0487-48DF-B37C-2CBF223288EBQ38091377-8CCDB700-C091-4514-AD0E-FB678C03719BQ38112350-7B2DA5D4-FA9E-47E1-9497-6A919DA467A6Q38195038-FFF491A2-1EF0-49A2-9FF7-A9E5D256A5ACQ38588167-4F738138-4DAC-4186-AD50-AFCDE92DB0A6Q38654368-264FB816-CA1E-41E4-8D3A-731AF0374931Q38688039-D4BA905A-7058-4F95-B5DE-2DFD3BCCFD41Q38797529-87EB07CF-8BE8-4E64-9719-195F752DA6DCQ38873927-5357F237-5DE6-465F-AA1F-8BA82E670AB4
P2860
Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Oxidative stress, redox signal ...... rmacological cardioprotection.
@ast
Oxidative stress, redox signal ...... rmacological cardioprotection.
@en
type
label
Oxidative stress, redox signal ...... rmacological cardioprotection.
@ast
Oxidative stress, redox signal ...... rmacological cardioprotection.
@en
prefLabel
Oxidative stress, redox signal ...... rmacological cardioprotection.
@ast
Oxidative stress, redox signal ...... rmacological cardioprotection.
@en
P2093
P2860
P50
P356
P1476
Oxidative stress, redox signal ...... armacological cardioprotection
@en
P2093
Anna Vávrová
Martin Stěrba
Olga Popelová
Vladimír Geršl
P2860
P304
P356
10.1089/ARS.2012.4795
P577
2012-10-12T00:00:00Z